Chrisomalis highlights Immuneering’s novel dual MEK inhibitor atebimetinib, its ability to address MAPK-driven tumors, strong clinical collaborations with Regeneron and Eli Lilly, and promising phase 2a results in pancreatic cancer as key attractive factors.
SA Asks: What’s the most attractive biotech stock right now?
